PT Inquest is an online journal club. Hosted by Jason Tuori, Megan Graham, and Chris Juneau, the show looks at an article every week and discusses how it applies to current physical therapy practice.
…
continue reading
Content provided by ReachMD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by ReachMD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
Managing Treatment-Related Toxicities With JAK Inhibitor Therapy in Myelofibrosis
MP3•Episode home
Manage episode 429718954 series 3128163
Content provided by ReachMD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by ReachMD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
CME credits: 1.00
Valid until: 19-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/managing-treatment-related-toxicities-with-jak-inhibitor-therapy-in-myelofibrosis/26511/
Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly improve patient outcomes. Stay informed on managing ruxolitinib intolerance and recognizing a failure to optimize therapeutic results so that you can enhance care for your patients.
…
continue reading
Valid until: 19-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/managing-treatment-related-toxicities-with-jak-inhibitor-therapy-in-myelofibrosis/26511/
Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly improve patient outcomes. Stay informed on managing ruxolitinib intolerance and recognizing a failure to optimize therapeutic results so that you can enhance care for your patients.
590 episodes
MP3•Episode home
Manage episode 429718954 series 3128163
Content provided by ReachMD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by ReachMD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
CME credits: 1.00
Valid until: 19-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/managing-treatment-related-toxicities-with-jak-inhibitor-therapy-in-myelofibrosis/26511/
Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly improve patient outcomes. Stay informed on managing ruxolitinib intolerance and recognizing a failure to optimize therapeutic results so that you can enhance care for your patients.
…
continue reading
Valid until: 19-07-2025
Claim your CME credit at https://reachmd.com/programs/cme/managing-treatment-related-toxicities-with-jak-inhibitor-therapy-in-myelofibrosis/26511/
Primary myelofibrosis is a complex disease requiring precise treatment strategies. Effective selection and sequencing of JAK inhibitors, particularly for cytopenic myelofibrosis, can significantly improve patient outcomes. Stay informed on managing ruxolitinib intolerance and recognizing a failure to optimize therapeutic results so that you can enhance care for your patients.
590 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.